News - Oncology

Filter

Current filters:

Oncology

Popular Filters

1 to 25 of 1535 results

EMA’s CHMP backs approval of two new treatment options for rare cancers

EMA’s CHMP backs approval of two new treatment options for rare cancers

26-07-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use, at its July meeting,…

BiotechnologyEuropeFinancialGilead SciencesImbruvicaJanssen BiotechJohnson & JohnsonOncologyRegulationZydelig

Xultophy, Accofil and Busulfan recommended by EMA/CHMP

26-07-2014

At its July 2014 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human…

AccofilAccord HealthcareBiosimilarsBusulfanDiabetesEuropeFresenius KabiImmunologicalsNovo NordiskOncologyPharmaceuticalRegulationXultophy

Is Europe putting cancer research at risk?

25-07-2014

The European Society for Medical Oncology (ESMO) has expressed concern that the proposed European Union…

EuropeOncologyPharmaceuticalRegulationResearch

Taiho Pharma and Sumitomo Dainippon both invest in Remiges BioPharma Fund

25-07-2014

Japanese oncology-focussed drugmaker Taiho Pharmaceutical has said that it will be investing $30 million…

BiotechnologyDainippon Sumitomo PharmaFinancialJapanOncologyRemiges BioPharma FundTaiho Pharmaceutical

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

25-07-2014

German drug major Bayer and Onyx Pharmaceuticals, an Amgen subsidiary (Nasdaq: AMGN), have said that…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Sandoz application for biosimilar Neupogen accepted by US FDA

25-07-2014

The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarzio

Bristol-Myers and Ono Pharma enter Asia oncology accord

Bristol-Myers and Ono Pharma enter Asia oncology accord

24-07-2014

US pharma major Bristol-Myers Squibb and Japan’s Ono Pharmaceutical have signed a strategic collaboration…

Asia-PacificBristol-Myers SquibbJapanLicensinglirilumabMelanomaOncologyOno PharmaceuticalOpdivoPharmaceuticalurelumabYervoy

Currency takes toll on Roche first-half results

Currency takes toll on Roche first-half results

24-07-2014

Swiss pharma major Roche, the world’s leading oncology company, this morning posted first-half 2014…

FinancialOncologyPharmaceuticalRocheSwitzerland

US FDA approves Gilead’s Zydelig for three types of blood cancers

US FDA approves Gilead’s Zydelig for three types of blood cancers

24-07-2014

The US Food and Drug Administration late yesterday approved Zydelig (idelalisib), a new drug from US…

BiotechnologyGilead SciencesidelalisibOncologyRegulationUSAZydelig

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

23-07-2014

The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending…

Astellas PharmaBristol-Myers SquibbOncologyPharmaceuticalRegulationUKXtandiYervoy

Zeltia diversifying its business pharma model to finance R&D pipeline

22-07-2014

PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying…

AplidinBiotechnologyChugai PharmaceuticalGP PharmLicensingOncologyPharmaMarPM 1183PolitrateResearchZeltia

Halozyme resumes enrolment and dosing of patients under revised protocol with US FDA

Halozyme resumes enrolment and dosing of patients under revised protocol with US FDA

22-07-2014

US-based pharmaceutical company Halozyme Therapeutics has said it is once again enrolling and dosing…

Halozyme TherapeuticsHyaluronidaseOncologyPancreatic cancerPEGylationPharmaceuticalRegulationUSA

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

22-07-2014

Anglo-Swedish drug major AstraZeneca says that its global biologics research and development arm MedImmune…

AdvaxisADXS-HPVAstraZenecaBiotechnologyMedImmuneOncologyPapillomavirusResearchSweden

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

22-07-2014

Australian biotech company Regeneus has expanded its portfolio to include licensing of global rights…

AustraliaBiotechnologyFinancialOncologyOsteosarcomaRegeneusResearchSarcoma

New cancer drugs approvals in Canada delayed due to extra layer of bureaucratic review

New cancer drugs approvals in Canada delayed due to extra layer of bureaucratic review

21-07-2014

The organization that reviews oncology medicines in Canada may unnecessarily delay approvals while cancer…

BevacizumabCanadaFraser InstituteOncologyPharmaceuticalRegulation

Queen's University Belfast researchers' breakthrough leads to new clinical trial in bowel cancer

Queen's University Belfast researchers' breakthrough leads to new clinical trial in bowel cancer

21-07-2014

Cancer Research UK scientists have discovered how two genes – called MEK and MET – cause bowel cancer…

Colorectal cancerOncologyPharmaceuticalResearchUKUniversity Belfast

PharmaMar and Chugai link up to commercialize Aplidin in Europe

17-07-2014

Spanish drugmaker Zeltia, through its biotech subsidiary PharmaMar, and Japan’s Chugai Pharmaceutical…

AplidinBiotechnologyChugai PharmaceuticalEuropeLicensingOncologyPharmaMarplitidepsinZeltia

Trametinib and dabrafenib gives overall survival benefit compared to vemurafenib

Trametinib and dabrafenib gives overall survival benefit compared to vemurafenib

17-07-2014

GlaxoSmithKline says that the Independent Data Monitoring Committee (IDMC) has recommended a Phase III…

BRAFdabrafenibGlobalGSKMetastatic cutaneous melanomaOncologyPharmaceuticalResearchtrametinibvemurafenib

Chugai gains marketing rights for Helsinn’s palonosetron and NEPA for chemo nausea

Chugai gains marketing rights for Helsinn’s palonosetron and NEPA for chemo nausea

17-07-2014

Japanese drugmaker Chugai, which is majority-owned by Swiss drug major Roche, has gained marketing rights…

AloxiAntiemeticsChemotherapy-induced nauseaChugai PharmaceuticalHelsinnOncologypalonosetron

Pfizer to acquire generics firm InnoPharma for up to $360 million

Pfizer to acquire generics firm InnoPharma for up to $360 million

17-07-2014

Having failed (so far) in its mega billion dollar ($116 billion) attempt to buy Anglo-Swedish drug major…

GenericsInnoPharmaMergers & AcquisitionsOncologyOphthalmicsPfizer

1 to 25 of 1535 results

Back to top